Baird Medical Investment Holdings Limited Asset Resilience Ratio

Latest as of March 2025: 0.38%

Baird Medical Investment Holdings Limited asset resilience ratio. Baird Medical Investment Holdings Limited (BDMD) has an Asset Resilience Ratio of 0.38% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BDMD days of operational coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$295.75K
Cash + Short-term Investments

Total Assets

$77.96 Million
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Baird Medical Investment Holdings Limited (2019–2024)

Asset resilience ratio of Baird Medical Investment Holdings Limited from 2019 to 2024. This chart shows how Baird Medical Investment Holdings Limited's Asset Resilience Ratio has changed over time. Read how much debt does Baird Medical Investment Holdings Limite carry for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Baird Medical Investment Holdings Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Baird Medical Investment Holdings Limite asset portfolio.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $295.75K 0.38%
Total Liquid Assets $295.75K 0.38%

Asset Resilience Insights

  • Limited Liquidity: Baird Medical Investment Holdings Limited maintains only 0.38% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Baird Medical Investment Holdings Limited Industry Peers by Asset Resilience Ratio

Compare Baird Medical Investment Holdings Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shenzhen New Industries Biomedical
SHE:300832
Medical Devices 9.95%
Double Medical Technology Inc
SHE:002901
Medical Devices 12.59%
BMC Medical Co. Ltd. A
SHE:301367
Medical Devices 44.96%
Emvision Medical Devices Ltd
AU:EMV
Medical Devices 0.06%
Hironic Co. Ltd
KQ:149980
Medical Devices 17.42%
DRGEM Corporation
KQ:263690
Medical Devices 2.12%
Oncosil Medical Ltd
AU:OSL
Medical Devices 0.00%
Adherium Ltd
AU:ADR
Medical Devices 15.45%

Baird Medical Investment Holdings Limited Asset Resilience Ratio by Year (2019–2024)

Baird Medical Investment Holdings Limited asset resilience ratio by year from 2019 to 2024. The table below shows the annual Asset Resilience Ratio data for Baird Medical Investment Holdings Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.38% $295.75K $77.96 Million +0.17pp
2023-12-31 0.21% $120.48K $56.71 Million -0.25pp
2022-12-31 0.46% $197.00K $42.62 Million -1.10pp
2021-12-31 1.56% $407.50K $26.12 Million +1.18pp
2020-12-31 0.38% $65.11K $17.02 Million +0.07pp
2019-12-31 0.31% $36.62K $11.76 Million --
pp = percentage points

About Baird Medical Investment Holdings Limited

NASDAQ:BDMD USA Medical Devices
Market Cap
$4.30 Million
Market Cap Rank
#28803 Global
#5919 in USA
Share Price
$0.12
Change (1 day)
-15.22%
52-Week Range
$0.12 - $3.44
All Time High
$11.46
About

Baird Medical Investment Holdings Limited, together with its subsidiaries, engages in research, development, manufacturing, and sales of microwave ablation and other medical devices in the People's Republic of China. The company offers microwave ablation apparatus and needles; long microwave ablation needles; and fine microwave ablation needles for the treatment of benign and malignant tumors, in… Read more